railway hotel sawbridgeworth

New Web site for Patients and Caregivers NEW YORK, Jan. 3 /PRNewswire/ -- Today, the Foundation for Clinical Research in Inflammatory Bowel Disease launched myIBD.org, a new information site designed for those concerned about inflammatory bowel disease, the collective term for Crohns disease, ulcerative colitis and indeterminate colitis. IBD affects over one million Americans and is a chronic, lifelong disease that has no known cause or cure. "We want patients and their caregivers to be able to access the best information available from the leading authorities on IBD," said Jane Present, co-founder and executive director of the Foundation for Clinical Research in IBD. "Thats why we worked with members of our scientific advisory committee, which includes IBD specialists and thought leaders from the countrys leading institutions, to develop the content for myIBD.org." The patient education section of the site includes an overview of IBD and the therapies used to treat the disease. In addition, myIBD.org includes transcripts of the Foundations Advances in Inflammatory Bowel Disease patient education programs, which it has hosted in over 70 cities throughout the United States. An "Ask the Specialist" section also provides a more in-depth look at questions that IBD patients and their caregivers may have. In addition to providing information to patients, the Foundation for Clinical Research in IBD is striving to enhance the array of effective medications available to treat IBD, as well as to encourage young gastroenterologists to pursue clinical careers in IBD. Therefore, myIBD.org contains information devoted to clinicians that outlines the opportunities available through the Foundation. Finally, the site will include information about current clinical trials and how patients can participate. MyIBD.org is published by the nonprofit organization the Foundation for Clinical Research in IBD and underwritten through unrestricted educational grants from Abbott Laboratories, Centocor, Inc., Procter & Gamble Pharmaceuticals, Salix Pharmaceuticals, Inc., and Shire USA Pharmaceuticals Inc.